Bharat Biotech, a global leader in vaccine innovation, developing vaccines for infectious diseases has announced the price of COVAXIN®. More than 50% of the vaccine capacities have been reserved for the Central Government at a price of Rs150/- which is distributed for free by the Govt. of India.
Makers of COVAXIN also announced the price of the vaccine for the State Governments and the Private hospitals, the company in their official twitter handle said India’s first indigenous COVID-19 vaccine will be priced at Rs. 600/- for the State Governments, while it will be priced Rs. 1200/- for private hospitals.
COVAXIN price explained
Bharat Biotech – COVAXIN® Announcement pic.twitter.com/cKvmFPfKlr
— BharatBiotech (@BharatBiotech) April 24, 2021
Bharat Biotech’s innovation COVAXIN® has unique features.
- Proven, Time-tested, Vero Cell Technology, Whole Virion, Inactivated vaccine
- Excellence safety profile with 6 publications in peer-reviewed journals
- Formulated with Adjuvants to boost immune response
- Ready-to-use multi-dose vial in liquid presentation, without reconstitution and no sub-zero storage.
- The distinct feature of having a 28 -day open vial policy. Once opened, the vial can be stored at 2-8 degrees centigrade for 28 days, thereby reducing vaccine wastage.
- Phase 3 study demonstrated an overall 78% efficacy against COVID-19 and 100% efficacy against severe disease, thereby reducing hospitalizations.
COVAXIN® is an inactivated and highly purified vaccine, making manufacturing expensive due to very low process yields. All costs towards product development, manufacturing facilities, and clinical trials were deployed primarily using internal funding and resources from Bharat Biotech.
Recovering costs is essentials in the journey of innovation towards other vaccines such as intranasal COVID-19, Chikungunya, Zika, Cholera, and others. Our core mission for the last 25 years has been to provide affordable, world-class healthcare solutions for the globe.
Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated “We thank you for your support and encouragement to continue our mission forward in overcoming life-threatening infectious diseases.”
